GBA1 and Parkinson disease: Specifically, we tested the effect of G2019S LRRK2 on N370S GBA1, a combination observed in Ashkenazi Jewish PD patients [62–64] and on L444P GBA1 variant, previously reported in a Brazilian family [54].